市场调查报告书
商品编码
1592596
欧洲抗体发现市场预测至 2030 年 - 区域分析 - 按抗体类型、性质、服务和最终用户Europe Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type, Nature, Services, and End User |
2022年欧洲抗体发现市值为8,244.4111亿美元,预计2030年将达到1,3294.816亿美元;预计2022年至2030年复合年增长率为6.2%。
癌症发生率上升推动欧洲抗体发现市场
根据全球癌症观察站 (GLOBOCAN) 2020 年发布的估计,全球有 1,930 万癌症病例。到 2030 年 1 月,癌症倖存者人数预计将达到 2,210 万,这主要与人口老化有关。肺癌、乳癌、大肠癌、摄护腺癌和乳癌是最常见的癌症类型。癌症发生率的上升引起了全世界的关注。以下是 2020 年全球报告的常见癌症病例清单。
2020 年全球新癌症病例
先生。
癌症类型
案件数量(百万)
资料来源:世界卫生组织,2020 年 2 月
癌症现在是一种生活方式疾病,常见于饮食习惯不健康和缺乏体能活动的人。经常饮酒和吸烟会增加患癌症的风险。低收入和中等收入国家的慢性传染病可进一步加剧癌症危险因子。癌症发生率的激增表明需要创新的癌症治疗方法。单株抗体是一类有前景的标靶抗癌药物,可增强免疫系统抑制癌细胞活性和消除癌细胞的天然能力。抗体药物偶联物(ADC)在癌症治疗中也显示出有希望的结果。此外,现代生物技术的进步使研究人员和公司能够提供精心设计的新型抗体,为成功治疗各种类型的癌症铺平道路。因此,不同类型癌症发生率的迅速上升促进了抗体发现市场的成长。
欧洲抗体发现市场概况
欧洲抗体发现市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。该地区在全球市场中占有重要份额。由于单株抗体在研发应用、癌症治疗和免疫疾病管理的使用激增,预计未来几年将强劲成长。此外,对患者资料管理系统的需求不断增长、慢性病的流行以及政府实施抗体服务的倡议预计将为法国、义大利和西班牙等国家的抗体发现市场提供成长机会。
欧洲抗体发现市场收入及 2030 年预测(十亿美元)
欧洲抗体发现市场细分
欧洲抗体发现市场按抗体类型、性质、服务、最终用户和国家分类。
根据抗体类型,欧洲抗体发现市场分为单株抗体、多株抗体等。到 2022 年,单株抗体领域将占据欧洲最大的抗体发现市场。
就性质而言,欧洲抗体发现市场分为人类和人源化、嵌合和鼠类。到 2022 年,人类和人源化细分市场将占据欧洲最大的抗体发现市场。
依服务划分,欧洲抗体发现市场分为噬菌体展示、杂交瘤、基因改造动物、单细胞和酵母展示。到 2022 年,噬菌体展示领域将占据欧洲最大的抗体发现市场。
根据最终用户,欧洲抗体发现市场分为製药和生技公司、研究实验室等。到 2022 年,製药和生物技术公司领域将占据欧洲最大的抗体发现市场。
根据国家/地区,欧洲抗体发现市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。 2022 年,德国在欧洲抗体发现市场份额中占据主导地位。
Charles River Laboratories International Inc、Creative Biolabs Inc、Evotec SE、Sartorius AG、Aragen Life Sciences Ltd、Twist Bioscience Corp 和 Biocytogen Pharmaceuticals 北京有限公司是欧洲抗体发现市场上的一些领先公司。
The Europe antibody discovery market was valued at US$ 8,24,441.11 million in 2022 and is expected to reach US$ 13,29,481.60 million by 2030; it is estimated to register a CAGR of 6.2% from 2022 to 2030.
Rising Incidence of Cancer Drives Europe Antibody Discovery Market
As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the world. By January 2030, the population of cancer survivors is estimated to reach 22.1 million, which can be primarily associated with the aging of the population. Lung, breast, colorectal, prostate, and breast are among the most commonly reported cancer types. The rising incidences of cancer have raised concerns worldwide.
Cancer is now a lifestyle disease commonly seen among people with unhealthy eating habits and those who don't engage much in physical activities. The frequent consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody-drug conjugates (ADCs) have also shown promising results in cancer treatment. Further, progress in modern biotechnology allows researchers and companies to provide well-designed novel antibodies, paving the way for successful treatments of various types of cancer. Thus, the burgeoning incidence of different types of cancer boosts the antibody discovery market growth.
Europe Antibody Discovery Market Overview
The European antibody discovery market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global market. It is expected to register a robust growth rate in the coming years owing to the surging use of monoclonal antibodies in R&D applications, cancer therapies, and immunological disorder management. Further, the rising need for patient data management systems, the prevalence of chronic diseases, and government initiatives for the implementation of antibody services are expected to provide growth opportunities for the antibody discovery market in countries such as France, Italy, and Spain.
Europe Antibody Discovery Market Revenue and Forecast to 2030 (US$ Billion)
Europe Antibody Discovery Market Segmentation
The Europe antibody discovery market is categorized into antibody type, nature, services, end user, and country.
Based on antibody type, the Europe antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest Europe antibody discovery market share in 2022.
In terms of nature, the Europe antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held the largest Europe antibody discovery market share in 2022.
By services, the Europe antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held the largest Europe antibody discovery market share in 2022.
Based on end user, the Europe antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held the largest Europe antibody discovery market share in 2022.
Based on country, the Europe antibody discovery market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe antibody discovery market share in 2022.
Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd. are some of the leading companies operating in the Europe antibody discovery market.